Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Institutes of Health (NIH) has agreed to award a two year $1.35m grant to DiscoveryBioMed's (DBM) Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program.
Subscribe to our email newsletter
The grant is expected to support the validation and prioritization of several lead CFCL chemical classes, drugs targeting the most common cystic fibrosis (CF) disease-causing mutation.
DBM expects to collaborate with Zsuzsanna Bebok, Karl Fu and Jim Collawn of the CF Research Center at the University of Alabama at Birmingham and Bill Guggino of the Johns Hopkins CF Research Center.
DBM CEO Erik Schwiebert said these grant dollars are essential to continue the drug discovery program.
"DBM decided early in the process to screen for drugs that correct the most common CF mutation; screening over 75,000 small molecules on a disease-relevant human cell platform, a bronchial epithelial cell line derived from the lung of a CF patient," Schwiebert said.